{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T07:25:56Z","timestamp":1753601156656},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Clostridioides-difficile-Infektionen (CDI) sind typische Komplikationen einer Antibiotikatherapie. Wenn auch die durch C. diff. verursachten Krankheitsbilder bis  zum toxischen Megakolon mit letalen Verl\u00e4ufen reichen k\u00f6nnen, sind leichte Verlaufsformen mit unkomplizierter Diarrhoe bei Weitem am h\u00e4ufigsten. Auch die Behandlung dieser Krankheitsbilder sollte leitliniengerecht erfolgen. Die zurzeit g\u00fcltigen internationalen Leitlinien sind bez\u00fcglich der Therapie der leichten Infektion mit Metronidazol aber widerspr\u00fcchlich. Vor diesem Hintergrund erfolgte eine selektive Literaturrecherche zu Leitlinien und Behandlungsstudien zum Einsatz von Metronidazol bei leichter CDI. Die Auswertung randomisierter kontrollierter Studien zeigt eine statistische \u00dcberlegenheit von Vancomycin gegen\u00fcber Metronidazol (NNT\u00a016). Unter Einbeziehung gro\u00dfer Kohortenstudien reduziert sich dieser Unterschied in der Effektivit\u00e4t auf 2,5\u200a% (NNT 40). Inkonsistente Kriterien zur Definition einer leichten CDI, unterschiedliche Dosierungen, Applikationen und Zeitintervalle (z.\u200aB. zus\u00e4tzliche Gabe von Metronidazol i.\u200av.) sowie der retrospektive Charakter mancher Studien verhindern das Erkennen m\u00f6glicher Einfl\u00fcsse von St\u00f6rgr\u00f6\u00dfen bei dieser Bewertung. Dennoch kann eine leichte CDI erfolgreich mit Metronidazol behandelt werden; andere Empfehlungen insbesondere amerikanischer Gesellschaften sollten deshalb kritisch bewertet werden. Wichtig ist, dass diese Therapieempfehlung nicht f\u00fcr Patienten mit chronisch entz\u00fcndlichen Darmerkrankungen oder andere Patienten mit relevanten Komorbidit\u00e4ten gilt.<\/jats:p>","DOI":"10.1055\/a-1190-5735","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T22:51:20Z","timestamp":1597272680000},"page":"778-784","source":"Crossref","is-referenced-by-count":2,"title":["Behandlung der leichten Clostridioides-difficile-Infektion \u2013 hat Metronidazol noch einen Stellenwert?"],"prefix":"10.1055","volume":"58","author":[{"given":"Andreas","family":"Stallmach","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin IV (Gastroenterologie, Hepatologie und Infektiologie), Universit\u00e4tsklinikum Jena, Friedrich-Schiller-Universit\u00e4t Jena, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Katzer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin IV (Gastroenterologie, Hepatologie und Infektiologie), Universit\u00e4tsklinikum Jena, Friedrich-Schiller-Universit\u00e4t Jena, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Reuken","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin IV (Gastroenterologie, Hepatologie und Infektiologie), Universit\u00e4tsklinikum Jena, Friedrich-Schiller-Universit\u00e4t Jena, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1099\/ijsem.0.002415","article-title":"List of new names and new combinations previously effectively, but not validly, published","volume":"67","author":"A Oren","year":"2017","journal-title":"Int J Syst Evol Microbiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/0003-4819-145-10-200611210-00008","article-title":"Narrative review: the new epidemic of Clostridium difficile-associated enteric disease","volume":"145","author":"J G Bartlett","year":"2006","journal-title":"Annals of internal medicine"},{"key":"ref3","first-page":"1182","article-title":"Clostridium Difficile Infection: What Is Currently Available for Treatment?","volume":"57","author":"A Stallmach","year":"2016","journal-title":"Der Internist"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.anaerobe.2015.08.002","article-title":"Factors predictive of severe Clostridium difficile infection depend on the definition used","volume":"37","author":"N Khanafer","year":"2016","journal-title":"Anaerobe"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"F A Zar","year":"2007","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"T J Louie","year":"2011","journal-title":"The New England journal of medicine"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"S H Cohen","year":"2010","journal-title":"Infection control and hospital epidemiology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","article-title":"Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections","volume":"108","author":"C M Surawicz","year":"2013","journal-title":"The American journal of gastroenterology"},{"issue":"S 02","key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection","volume":"20","author":"S B Debast","year":"2014","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"ref12","first-page":"418","article-title":"S2k-guideline gastrointestinal infectious diseases and Whipple\u2019s disease","volume":"53","author":"S Hagel","year":"2015","journal-title":"Zeitschrift fur Gastroenterologie"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cmi.2017.12.022","article-title":"Update of treatment algorithms for Clostridium difficile infection","volume":"24","author":"R E Ooijevaar","year":"2018","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"ref14","first-page":"CD004610","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults","volume":"3","author":"R L Nelson","year":"2017","journal-title":"The Cochrane database of systematic reviews"},{"key":"ref15","first-page":"505","article-title":"Treatment of Acute and Recurrent Clostridium Difficile Infections: What Is New?","volume":"59","author":"A von Braun","year":"2018","journal-title":"Der Internist"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1055\/a-0585-9595","article-title":"Neue Leitlinien und Daten zu Clostridium difficile \u2013 Was \u00e4ndert sich?","volume":"143","author":"C L\u00fcbbert","year":"2018","journal-title":"Deutsche medizinische Wochenschrift"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/jac\/dku261","article-title":"Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison","volume":"69","author":"O A Cornely","year":"2014","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10096-015-2538-z","article-title":"The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations","volume":"35","author":"S D Goldenberg","year":"2016","journal-title":"European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology"},{"key":"ref19","first-page":"e2778","article-title":"Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review","volume":"10","author":"L A Al Momani","year":"2018","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(83)91036-X","article-title":"Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis","volume":"2","author":"D G Teasley","year":"1983","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","article-title":"Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea","volume":"22","author":"C Wenisch","year":"1996","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"S Johnson","year":"2014","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/PHAR.1002","article-title":"A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs","volume":"32","author":"F Le","year":"2012","journal-title":"Pharmacotherapy"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/IPC.0000000000000375","article-title":"Initial therapy for mild to moderate clostridium difficile infection. Exploring the role of oral metronidazole versus vancomycin in 168 hospitalized patients","volume":"24","author":"J Siegfried","year":"2016","journal-title":"Infect Dis Clin Pract"},{"issue":"S 01","key":"ref25","first-page":"2016","article-title":"Efficacy of bezlotoxumab in patients receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridium difficile infection (CDI)","volume":"3","author":"E R Dubberke","year":"2016","journal-title":"Open forum infectious diseases"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamainternmed.2016.9045","article-title":"Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection","volume":"177","author":"V W Stevens","year":"2017","journal-title":"JAMA internal medicine"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e12867","DOI":"10.1111\/tid.12867","article-title":"Comparison of outcomes with vancomycin or metronidazole for mild-to-moderate Clostridium difficile associated diarrhea among solid organ transplant recipients: A retrospective cohort study","volume":"20","author":"C T Nguyen","year":"2018","journal-title":"Transplant infectious disease: an official journal of the Transplantation Society"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"ofz492","DOI":"10.1093\/ofid\/ofz492","article-title":"Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridioides difficile Infections","volume":"6","author":"J Yin","year":"2019","journal-title":"Open forum infectious diseases"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05900-3","article-title":"Clinical Predictors of Recurrence After Primary Clostridioides difficile Infection: A Prospective Cohort Study","author":"J R Allegretti","year":"2019","journal-title":"Digestive diseases and sciences"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/ajhp\/zxz032","article-title":"Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings","volume":"76","author":"H J Appaneal","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/AAC.02606-13","article-title":"Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease","volume":"58","author":"H A Horton","year":"2014","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"ref32","first-page":"1321","article-title":"August 2019 \u2013 AWMF-Registriernummer: 021-009","volume":"57","author":"T Kucharzik","year":"2019","journal-title":"Zeitschrift fur Gastroenterologie"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0018578718787439","article-title":"Impact of Delayed Oral Vancomycin for Severe Clostridium difficile Infection","volume":"54","author":"S Shah","year":"2019","journal-title":"Hosp Pharm"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1190-5735.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T22:52:23Z","timestamp":1597272743000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1190-5735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":31,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2020,8,12]]},"published-print":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1190-5735","relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}